593 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
be made by independent tax counsel designated by the Company and reasonably acceptable to you (“Independent Tax Counsel”), whose determination shall … be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (“Independent … required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
and (ii) has exercised independent judgment in evaluating its participation in the purchase of the Securities. Each Investor acknowledges … that a possibility of total loss exists.
4.9 Independent Investment Decision. Such Investor understands that nothing in the Transaction Agreements or any other
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
, Samarth Kulkarni and Cameron Turtle, each of whom is a current member of the Board, qualify as “independent directors” as defined by the Nasdaq … .
The Board has also determined that each member of the Audit Committee (as defined below) and Compensation Committee (as defined below) is independent
8-K
EX-99.2
h4zle3
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-10.11
mcj7609ucpzkgujw7
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-10.25
qap72nq
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-3.6
9kzlw7qwkjnh14qrl
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
m6d92vj j92eeu
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
EX-10.1
yqfyku 098lf8eux1x
15 Aug 24
Business combination disclosure
4:17pm
8-K
EX-10.1
wqdol2qn1wc57ie
15 Aug 24
Entry into a Material Definitive Agreement
4:15pm
425
b7w9xn73pr c1nj9ux2
9 Aug 24
Business combination disclosure
8:35am
424B3
5q1swnrs9l1ssmv4f
1 Aug 24
Prospectus supplement
4:10pm